ProShare Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

ProShare Advisors’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-42,573	Closed	-$216K	–	1756
2015 Q3	$216K	Sell	42,573 -2,019	-5%	-$10.7K	﹤0.01%	1282
2015 Q2	$234K	Sell	44,592 -180	-0.4%	-$951	﹤0.01%	1426
2015 Q1	$222K	Buy	44,772 +7,970	+22%	+$39.3K	﹤0.01%	1665
2014 Q4	$192K	Buy	36,802 +8,170	+29%	+$41.7K	﹤0.01%	1749
2014 Q3	$138K	Sell	28,632 -5,105	-15%	-$27.4K	﹤0.01%	2106
2014 Q2	$190K	Sell	33,737 -8,672	-20%	-$52.7K	﹤0.01%	2198
2014 Q1	$305K	Buy	42,409 +18,275	+76%	+$121K	﹤0.01%	2228
2013 Q4	$148K	Buy	24,134 +4,786	+25%	+$28.8K	﹤0.01%	1277
2013 Q3	$116K	Buy	19,348 +8,850	+84%	+$42.3K	﹤0.01%	2382
2013 Q2	$41K	Buy	+10,498	New	+$39.1K	﹤0.01%	2364

Other funds holding SVA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

ProShare Advisors's SVA Position: Q4 2015 in Review

ProShare Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q4 2015, closing a stake of 42,573 shares — an estimated $216K sold.

ProShare Advisors first reported a position in SVA in Q2 2013 and held it in 10 quarters. The position peaked at $305K in Q1 2014. 40 funds tracked by Wall St. Rank hold SVA as of Q4 2015.

ProShare Advisors reported no remaining Sinovac Biotech, Ltd position as of Q4 2015 after selling out during the quarter.
ProShare Advisors sold 42,573 Sinovac Biotech, Ltd shares in Q4 2015, an estimated $216K.
ProShare Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 10 quarters.
ProShare Advisors's Sinovac Biotech, Ltd position peaked at $305K in Q1 2014.
40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2015.

Based on ProShare Advisors's 13F filing for Q4 2015, filed 5 Feb 2016.